Data investigating the prognostic value of treatment with angiotensin converting enzyme inhibitors (ACEi) and receptor blockers (ARB) usually focusses on patients presenting with heart failure (HF) or acute myocardial infarction (AMI). However, by preventing adverse cardiac remodeling, ACEi/ARB may also decrease the risk of ventricular tachyarrhythmias and sudden cardiac death (SCD). Although ventricular tachyarrhythmias are associated with significant mortality and morbidity, only limited data are available focusing on the prognostic role of ACEi/ARB, when prescribed for secondary prevention of SCD. Therefore, this study comprehensively investigates the role of ACEi versus ARB in patients with ventricular tachyarrhythmias. A large retrospe...
Abstract Background Heart failure (HF) remains a significant cause of morbidity and mortality. Multi...
ObjectivesWhether beta-blockers reduce atrial arrhythmias and, when added to an angiotensin-converti...
Introduction: Ventricular remodeling starts very early after the onset of an acute myocardial infarc...
Background: Current treatment guidelines for arrhythmogenic right ventricular cardiomyopathy (ARVC) ...
Large-scale, placebo-controlled, randomized clinical trials have demonstrated that angiotensin-conve...
Ventricular arrhythmias (VA) are a major cause of sudden death. Life-threatening VA may be present i...
The remarkable scientific progress in the treatment of patients with heart failure (HF) and reduced ...
The relative superiority of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin recepto...
International guidelines recommend ICD implantation in patients with severe left ventricular dysfunc...
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have shown...
Objective: Few data exist to guide antiarrhythmic drug therapy for sustained ventricular tachycardia...
ObjectivesThis study was designed to identify all randomized clinical trial data evaluating angioten...
Objective: ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are widely prescribed in ...
INTRODUCTION AND OBJECTIVES: For patients with acute coronary syndrome (ACS) treated with percutaneo...
Aims Treatment with angiotensin converting enzyme inhibitor (ACEi)/angiotensin II receptors blockers...
Abstract Background Heart failure (HF) remains a significant cause of morbidity and mortality. Multi...
ObjectivesWhether beta-blockers reduce atrial arrhythmias and, when added to an angiotensin-converti...
Introduction: Ventricular remodeling starts very early after the onset of an acute myocardial infarc...
Background: Current treatment guidelines for arrhythmogenic right ventricular cardiomyopathy (ARVC) ...
Large-scale, placebo-controlled, randomized clinical trials have demonstrated that angiotensin-conve...
Ventricular arrhythmias (VA) are a major cause of sudden death. Life-threatening VA may be present i...
The remarkable scientific progress in the treatment of patients with heart failure (HF) and reduced ...
The relative superiority of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin recepto...
International guidelines recommend ICD implantation in patients with severe left ventricular dysfunc...
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have shown...
Objective: Few data exist to guide antiarrhythmic drug therapy for sustained ventricular tachycardia...
ObjectivesThis study was designed to identify all randomized clinical trial data evaluating angioten...
Objective: ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are widely prescribed in ...
INTRODUCTION AND OBJECTIVES: For patients with acute coronary syndrome (ACS) treated with percutaneo...
Aims Treatment with angiotensin converting enzyme inhibitor (ACEi)/angiotensin II receptors blockers...
Abstract Background Heart failure (HF) remains a significant cause of morbidity and mortality. Multi...
ObjectivesWhether beta-blockers reduce atrial arrhythmias and, when added to an angiotensin-converti...
Introduction: Ventricular remodeling starts very early after the onset of an acute myocardial infarc...